CJC-1295 Clinical Studies: What the Research Shows

You will see many confident claims online about what CJC-1295 does for muscle, fat loss, sleep and aging. This article goes back to the source. It summarises every published study we could verify, explains in plain English what each one measured, and is clear about what the research does not show. For background on how CJC-1295 works, start with our guide to what CJC-1295 is.

CJC-1295 is not approved by the FDA for any use. It is prescribed at a licensed physician's discretion after a medical review. This article is educational and is not medical advice.

Where CJC-1295 Came From

CJC-1295 was developed by the Canadian company ConjuChem in the early 2000s. It is a modified version of the first 29 amino acids of growth hormone releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. Natural GHRH lasts only minutes in the blood. ConjuChem's goal was a version that lasted days, so it could be given far less often. The key innovation, called a drug affinity complex or DAC, lets the peptide attach to albumin, the most common protein in the blood, which protects it from being broken down.

The Discovery Study in Rats (2005)

The first paper to describe CJC-1295 tested three related compounds in rats. CJC-1295 performed best: it produced a fourfold larger growth hormone response over two hours than unmodified GHRH, and it was still present in the blood beyond 72 hours, attached to albumin. This study explains why CJC-1295 lasts so long, but it was carried out in animals and tells us nothing directly about effects in people.

The First Human Trials (2006)

The most important human evidence comes from two randomised, double blind, placebo controlled trials published together in 2006. Healthy volunteers aged 21 to 61 received either CJC-1295 or a placebo by injection under the skin. The first trial tested single doses of increasing size; the second tested two or three doses given weekly or every other week, over 28 and 49 days.

The results were clear on hormone levels. After a single injection, growth hormone rose two to tenfold for six days or more and IGF-1 rose one and a half to threefold for nine to eleven days. The estimated half life of CJC-1295 was 5.8 to 8.1 days, and with repeated doses IGF-1 stayed above baseline for up to 28 days. The researchers concluded that CJC-1295 was safe and relatively well tolerated over the study period, particularly at 30 or 60 mcg per kg.

It is just as important to note what these trials did not measure. They did not look at muscle mass, body fat, strength, sleep, energy, skin or aging. They were short, and they enrolled only a few dozen healthy people. They show that CJC-1295 reliably raises growth hormone and IGF-1. They do not show that it produces any particular health benefit.

The Growth Hormone Pulse Study (2006)

Growth hormone is normally released in pulses, mostly during sleep, rather than at a steady level. A concern with any long acting stimulant is that it might flatten this natural rhythm. A second 2006 study tested this in healthy men aged 20 to 40. Blood was sampled every 20 minutes through the night before treatment and again one week after a single dose.

The researchers found that CJC-1295 increased trough and mean growth hormone secretion and IGF-1 production while preserving the natural pulse pattern. In other words, the peptide raised the baseline between pulses without switching off the body's own rhythm. This is useful for understanding how CJC-1295 works, but like the first trials, it measured hormones rather than health outcomes.

The Mouse Growth Study (2006)

Researchers also tested CJC-1295 in mice bred without the ability to make their own GHRH, which leaves them small. Given once daily, CJC-1295 normalised growth in these mice. This confirms that the peptide works through the GHRH pathway, but it is an animal model of a specific deficiency. It cannot be used to predict effects in healthy adults.

The Blood Protein Study (2009)

A later analysis used blood samples from 11 healthy young men taken before and one week after a single dose of CJC-1295. Using protein mapping techniques, the researchers identified changes in several serum proteins associated with growth hormone and IGF-1 activity, including forms of apolipoprotein A1 and transthyretin. The aim was to find markers of growth hormone action. It is an exploratory study, and it does not show whether these changes have any effect on health.

The Halted Phase II Trial (2006)

ConjuChem went on to test CJC-1295 in a larger Phase II trial in people with HIV associated abdominal fat, a condition where reducing visceral fat is a clinical goal. The study enrolled 192 participants across North and South America. In 2006 it was halted after the death of a study participant. The trial physician considered the most likely cause to be undiagnosed coronary artery disease rather than the drug, but development was stopped and the full results were never published in a peer reviewed journal. CJC-1295 never reached Phase III trials or approval.

A different GHRH analog, tesamorelin, did complete development and was later approved by the FDA for HIV associated abdominal fat. Its results are sometimes quoted as if they apply to CJC-1295, but they come from a different molecule with a different structure and dosing, and should not be borrowed as evidence for CJC-1295.

The Evidence at a Glance

StudyWho or what was studiedWhat was measuredMain findingWhat it does not showJetté 2005RatsGrowth hormone release and how long the peptide stays in the bloodCJC-1295 binds albumin and stays in plasma beyond 72 hoursAny effect in humansTeichman 2006Healthy adults aged 21 to 61, two placebo controlled trials of 28 and 49 daysGH, IGF-1, half life, safetyGH up 2 to 10 fold for 6 days or more, IGF-1 up 1.5 to 3 fold for 9 to 11 days, half life 5.8 to 8.1 daysBody composition, sleep, energy, long term safetyIonescu 2006Healthy men aged 20 to 40Overnight GH pulse pattern before and one week after a doseNatural GH pulses preserved; trough and mean GH and IGF-1 increasedClinical outcomesAlba 2006Mice lacking natural GHRHGrowthOnce daily CJC-1295 normalised growthEffects in adults or humansSackmann-Sala 200911 healthy young menBlood protein patterns one week after a doseChanges in several serum proteins linked to the GH and IGF-1 axisWhether those changes matter for healthPhase II trial, 2006People with HIV associated abdominal fatPlanned: body fat and safetyHalted after a participant death; results never fully publishedEfficacy for fat loss

What Has Never Been Studied

Putting the research together, several things have not been tested in any published CJC-1295 study:

• Body composition: no published human trial has measured changes in muscle or fat.
• Sleep, energy, mood or cognition: none of the studies measured these.
• Recovery from exercise or injury: not studied.
• Skin, hair or signs of aging: not studied.
• Long term safety: the longest published exposure was a few weeks.
• Specific groups: older adults beyond 61, people with chronic conditions, and combinations with other peptides have not been studied.

The FDA reflects this when it states that available clinical data are limited, while also citing serious adverse events including increased heart rate and systemic vasodilatory reaction. Our CJC-1295 side effects and safety guide covers these in detail.

How to Read CJC-1295 Claims Online

When a website says CJC-1295 builds muscle, burns fat, deepens sleep or slows aging, check what evidence it cites. Often the claim is based on what growth hormone does in general, on results from tesamorelin or approved growth hormone, or on personal reports. These are not the same as CJC-1295 research. A trustworthy source will separate what has been measured, which is hormone levels, from what is hoped or reported. You can see how we apply this in our honest look at CJC-1295 benefits and what the evidence shows, and our peptide and hormone glossary explains the technical terms used in these studies.

Conclusion

The published research on CJC-1295 is small but consistent on one point: it reliably raises growth hormone and IGF-1 for days after a single injection, while keeping the natural pulse pattern of growth hormone. The animal studies explain why it lasts so long and confirm that it works through the GHRH pathway. What the research does not show is any measured benefit for muscle, fat, sleep, energy or aging, and there is no long term safety data. The only larger trial was halted in 2006. Anyone considering CJC-1295 should weigh it with that picture in mind and under a physician's care. If you would like a physician to assess whether it is suitable for you, you can start your online assessment.